• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Thermo Fisher Scientific (TMO) Gains Fresh Attention As FBI Clearance Tests Its Undervalued Narrative

    Simply Wall St·07/14/2026 03:30:29
    Listen to the news

    Thermo Fisher Scientific (TMO) is back in focus after the FBI cleared its Applied Biosystems RapidINTEL Plus Cartridge for generating crime scene DNA profiles that can be searched within the national CODIS database.

    See our latest analysis for Thermo Fisher Scientific.

    The FBI clearance for RapidINTEL Plus and recent collaborations around mRNA therapies and advanced oral drug delivery arrive at a time when Thermo Fisher Scientific’s 1 month share price return of 12.61% contrasts with a year to date share price decline of 10.8%, while the 1 year total shareholder return of 24.71% points to stronger longer term momentum.

    If this kind of product driven story interests you, it can be useful to see what else is moving in related areas. You can start with 40 healthcare AI stocks

    Thermo Fisher Scientific looks like a powerful franchise in life sciences and forensic tools, and the recent rebound in the share price reflects that. The real issue now is whether that quality is already fully priced in.

    Most Popular Narrative: 10.5% Undervalued

    Thermo Fisher Scientific is trading at $528.51 against a narrative fair value of about $590.77, which sets up a clear valuation gap that analysts are trying to explain.

    The company's positioning as a trusted, end to end partner for pharma and biotech enables greater customer stickiness and deeper integration into high growth markets like clinical research, outsourcing (CDMO), and lab services, enhancing recurring revenue streams and supporting high single digit earnings growth over time. Proactive cost management, leveraging the PPI Business System and AI driven process improvements, is expected to continue expanding operating margins even in a muted demand environment, setting up for stronger net margin expansion as topline growth rebounds.

    Read the complete narrative.

    Want to see what sits behind that confidence in Thermo Fisher Scientific? The narrative leans heavily on recurring revenue, margin expansion and a specific earnings path. The exact mix of growth, profitability and valuation assumptions may surprise you.

    Result: Fair Value of $590.77 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Thermo Fisher Scientific’s narrative could be challenged if academic and government funding stays weak, or if China related pressures continue to weigh on revenue and margins.

    Find out about the key risks to this Thermo Fisher Scientific narrative.

    Next Steps

    If Thermo Fisher Scientific’s mixed signals leave you undecided, consider taking action while the story is still forming and weigh both sides using the 3 key rewards and 1 important warning sign

    Looking for more investment ideas beyond Thermo Fisher Scientific?

    If Thermo Fisher Scientific has sharpened your focus, do not stop here. Broaden your watchlist with other opportunities that fit different goals and risk levels.

    • Target potential mispricing by scanning 46 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
    • Strengthen your income stream by reviewing 8 dividend fortresses built around higher yielding companies that still prioritize resilience and consistency.
    • Lean toward stability by checking 80 resilient stocks with low risk scores that score well on financial health and historically lower risk profiles.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.